Aktis Oncology, Inc.
AKTS
$18.75
$0.030.16%
NASDAQ
| 12/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1.87M | 933.00K | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.87M | 933.00K | |||
| Cost of Revenue | 16.49M | 12.61M | |||
| Gross Profit | -14.62M | -11.67M | |||
| SG&A Expenses | 2.75M | 3.96M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.25M | 16.57M | |||
| Operating Income | -17.38M | -15.64M | |||
| Income Before Tax | -15.14M | -12.06M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.14M | -12.06M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.14M | -12.06M | |||
| EBIT | -17.38M | -15.64M | |||
| EBITDA | -16.68M | -15.19M | |||
| EPS Basic | -18.21 | -16.06 | |||
| Normalized Basic EPS | -11.38 | -10.04 | |||
| EPS Diluted | -18.21 | -16.06 | |||
| Normalized Diluted EPS | -11.38 | -10.04 | |||
| Average Basic Shares Outstanding | 831.20K | 750.70K | |||
| Average Diluted Shares Outstanding | 831.20K | 750.70K | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||